Synchron Pauses Trials of Its Next-Generation Stentrode Over a Lead Problem, Says Safety Is Not the Issue

Photo: Vitaly Gariev / Unsplash

The developer of a catheter-delivered brain-computer interface is cutting New York jobs and reworking a key cable before enrollment resumes.

Background

Synchron, a Brooklyn-based neurotechnology company [1], has built its pitch around a brain-computer interface (BCI) that does not require opening the skull. Its Stentrode is guided by catheter through the jugular vein and expanded inside the superior sagittal sinus, a large vein that runs alongside the motor cortex [4]. In practice, the approach has more in common with an angiography suite than with a neurosurgical operating room.

The clinical evidence so far comes from small, early studies. In the first-in-human SWITCH study, published in JAMA Neurology in January 2023, four men with amyotrophic lateral sclerosis (ALS) received the device; over a year of follow-up none had blood clots, vessel blockage, device migration or other serious device-related adverse events, and all used it to control a computer [4]. A six-patient U.S. early feasibility study, COMMAND, reported at the 2024 Congress of Neurological Surgeons meeting that all participants met its primary safety endpoint at 12 months [5].

In November 2025, Synchron announced a $200 million Series D round. It said the money would move its first-generation platform toward pivotal trials and commercial launch, fund a next-generation, higher-channel interface also delivered by catheter, and build out an engineering hub in San Diego [3]. At that point the company said the Stentrode had been placed in 10 patients with paralysis in U.S. and Australian trials [3].

What Happened

WIRED reported on Nov. 12 that Synchron had paused clinical trials of its second-generation device [2]. STAT followed on Nov. 13. It described the new device as a wireless version of the first-generation system and reported that company leaders said the pause was not safety related [1]. STAT and Medical Daily both reported that Synchron will eliminate jobs in New York, but neither gave a number [1][2].

Medical Daily summarized WIRED's reporting: the device did not perform as expected in its first study participants, and the problem involved the lead, the cable that connects the electrode array inside the blood vessel to the implanted electronics [2]. Medical Daily also reported that Synchron said it had found no associated safety issues, that the enrollment pause was voluntary rather than ordered by the FDA, and that the company plans to bring lead design and manufacturing in-house and upgrade the system before enrollment restarts [2]. A separate summary of the WIRED story said Synchron is also assembling a team in San Diego to develop an entirely new device [6].

The pause may explain a comment CEO Tom Oxley made the week before on a New York conference panel, where he sat alongside executives from competitors Neuralink and Precision Neuroscience. He said the company had "one particular component that we were caught up on," and noted that a single delayed part can slow an FDA submission [1]. STAT connected that remark to the pause [1]. Medtech veterans will recognize the pattern: the weakest link in a device is sometimes, quite literally, a link.

What Remains Unknown

The reporting reviewed for this article leaves several basic questions open. It does not say how many people received the second-generation device, how often or in what way the lead underperformed, how many jobs are being cut, or when enrollment might resume [2]. The statement that the pause is unrelated to safety comes from the company, and no data on the affected participants have been published.

Medical Daily listed newer studies, including one at two Toronto hospitals (NCT07446114) and a planned Australian study, each aiming to enroll about 10 people with ALS or related conditions [2]. The sources do not make clear which of these studies the pause covers. Medical Daily also reported that it is unknown whether a redesigned system will need new FDA review, and noted that no BCI is FDA-approved for general use [2].

The earlier safety record also needs context. SWITCH and COMMAND together enrolled 10 people in single-arm feasibility designs [4][5]. Those results show that the endovascular route can be done, but studies that small cannot establish long-term reliability, which is exactly what the lead problem calls into question.

What Comes Next

The next things to watch are a redesigned lead, a date for resuming enrollment, and any disclosure of what happened to the first participants who received the second-generation system. For interventional radiologists and neurointerventionalists, the larger question is whether a vessel-based implant can deliver consistent signal quality over years without a return trip to the operating room. Synchron's stated plan to own lead design and manufacturing in-house [2] suggests the company sees the cable as the problem to solve first.

This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.

References

  1. Merelli A, Broderick OR. Brain implant startup pauses trials. STAT (Morning Rounds). Nov 13, 2026. https://www.statnews.com/2026/11/13/health-news-brain-implant-startup-pauses-trials/

  2. Mercer C. Brain Implant Maker Synchron Pauses Trials of Its Wireless Stentrode, Saying the Pause Is Not Related to Safety. Medical Daily. Nov 17, 2026. https://www.medicaldaily.com/synchron-pauses-wireless-brain-implant-trials-481309

  3. Synchron. Synchron Raises $200 Million Series D to Advance Brain-Computer Interface Technology. Business Wire. Nov 6, 2025. https://businesswire.com/news/home/20251106150841/en/Synchron-Raises-%24200-Million-Series-D-to-Advance-Brain-Computer-Interface-Technology

  4. Lanese N. New "thought-controlled" device reads brain activity through the jugular. Live Science. Jan 12, 2023. https://www.livescience.com/brain-computer-interface-through-vein-safety

  5. Herpen R. No serious adverse events reported with Synchron brain-computer interface at 12 months. Healio. Oct 4, 2024. https://www.healio.com/news/neurology/20241004/no-serious-adverse-events-reported-with-synchron-braincomputer-interface-at-12-months

  6. Bioethics.com. Synchron Pauses Trials of Its Brain Implant Due to Performance Issues (summary of WIRED report). Nov 13, 2026. https://www.bioethics.com/archives/104717

Phillip Leblanc

What I cover

I write wellness and medical culture pieces for The Culture Desk RX: strangers sweating it out in a street sauna, doctors with unusual side hustles, and the general human comedy of trying to stay healthy. A good fraud story and a good sauna story have more in common than you’d think. Somebody’s always sweating.

I’ve seen everything from kickbacks dressed up as “consulting fees” to charities that are generous mostly to their own founders. If a dollar goes missing between the patient and the provider, I find it.

I focus on interventional radiology and the quiet evolution of robotic systems that are breaking medical ceilings, healing patients with catheters instead of scalpels. I believe in the good guys, so I write about altruistic causes: the nurses, doctors and nonprofits doing honest work with no PR team.

My Background

Growing up in East Durham, North Carolina, you learn two things: how to throw a jab and when to keep your mouth closed. My editor says it explains my interviewing style.

Journalistic Ethics

Vital Biomedical News is reader-funded and beholden to no one. We take no money from pharmaceutical or medical device companies, and neither do I. I don’t accept gifts, junkets or favors, and I don’t bankroll political causes. My only allegiance is to the paper trail.

I deal in documents, not anecdotes. Every claim is corroborated against primary sources: court filings, federal records, clinical data and the people who were actually in the room. Sources get candor, confidential sources get anonymity, and powerful institutions get scrutiny, whether they welcome it or not.

I’m unfailingly courteous to everyone I interview, including the people I’m investigating. Civility is not clemency.

Previous
Previous

FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Advanced Breast Cancer

Next
Next

FDA Approves Gazyva as First Drug for Primary Membranous Nephropathy